[HTML][HTML] Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
M Yang, C Lin, Y Wang, K Chen, H Zhang, W Li�- Genome Medicine, 2022 - Springer
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with�…
Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood�…
However, molecular determinants of response to ICIs remain incompletely understood�…
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung�…
Y Shi, Y Lei, L Liu, S Zhang, W Wang, J Zhao…�- Cancer�…, 2021 - Wiley Online Library
Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling�…
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling�…
[HTML][HTML] Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with�…
Y Xu, H Li, Z Huang, K Chen, X Yu…�- Translational Lung�…, 2020 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) prolong overall survival (OS) in patients
with advanced lung squamous cell carcinoma (LUSC). However, predictive and prognostic�…
with advanced lung squamous cell carcinoma (LUSC). However, predictive and prognostic�…
Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer
PURPOSE Although immune checkpoint inhibitors (ICI) have extended survival in patients
with non–small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently�…
with non–small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently�…
Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
J Frigola, A Navarro, C Carbonell, A Callejo…�- Molecular�…, 2021 - Wiley Online Library
Immunotherapy has transformed advanced non‐small cell lung cancer (NSCLC) treatment
strategies and has led to unprecedented long‐lasting responses in some patients. However�…
strategies and has led to unprecedented long‐lasting responses in some patients. However�…
[HTML][HTML] Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this�…
revolutionizing cancer treatment. To unravel the genomic determinants of response to this�…
[HTML][HTML] Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
[HTML][HTML] Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Abstract Aims Immune checkpoint inhibitors (ICIs) induce durable responses, but their
clinical benefits apply to only a subset of patients. Therefore, precisely predicting a patient's�…
clinical benefits apply to only a subset of patients. Therefore, precisely predicting a patient's�…